PPTA Twitter

PlasmaProteins #Alpha1 antitrypsin deficiency is a serious hereditary disorder. Each year, more than 900 #plasma donations are needed to treat just one person living with Alpha-1. bit.ly/2QF6N1B #PlasmaDonorsSaveLives pic.twitter.com/otLmJe8Qfa
About 24 hours ago.
PlasmaProteins We #AdvocateForPPTs so that individuals living with certain pre-existing conditions will have continued access to the #plasmaprotein therapies they need to lead healthy and productive lives. Learn more about PPTA’s advocacy efforts: bit.ly/2ICrQNP pic.twitter.com/SLLHjmLjku
2 days ago.

Plasma Protein Therapeutics Association

The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions.

Erica XLA

PPTA works globally to:

    • Advocate for access to and affordability of therapies for patients
    • Engage in constructive dialogue with regulatory agencies
    • Collaborate with patient advocacy organizations

PPTA also administers standards and programs that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100